Showing results (81-90 of 2,104) with videos related to
Sort By:
Pageof 211
CNS Drugs|May 14, 2015
Impact of Pharmacotherapy on Quality of Life in Patients with Parkinson's DiseasePablo Martinez-Martin, Carmen Rodriguez-Blazquez, Maria João Forjaz, et al.CNS Drugs|October 12, 2010
Dopamine receptor agonists for the treatment of early or advanced Parkinson's diseaseSantiago Perez-Lloret, Olivier RascolCNS Drugs|February 18, 2011
Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopramClaudio N Soares, Michael E Thase, Anita Clayton, et al.CNS Drugs|December 7, 2010
Achieving remission as a routine goal of pharmacotherapy in attention-deficit hyperactivity disorderJ Antoni Ramos-Quiroga, Miguel CasasCNS Drugs|April 8, 2010
Predictive factors of discontinuation and switch of cholinesterase inhibitors in community-dwelling patients with Alzheimer's disease: a 2-year prospective, multicentre, cohort studyVirginie Gardette, Sandrine Andrieu, Maryse Lapeyre-Mestre, et al.CNS Drugs|April 8, 2010
Olanzapine: in adolescents with schizophrenia or bipolar I disorderPaul L McCormackCNS Drugs|July 28, 2010
Awakenings and awareness recovery in disorders of consciousness: is there a role for drugs?Francesca Pistoia, Elisa Mura, Stefano Govoni, et al.CNS Drugs|September 3, 2010
The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implicationsRoger S McIntyre, Ka Young Park, Candy W Y Law, et al.CNS Drugs|November 25, 2010
Preventative strategies for early-onset bipolar disorder: towards a clinical staging modelRobert K McNamara, Jayasree J Nandagopal, Stephen M Strakowski, et al.CNS Drugs|September 11, 2009
Seizures in patients with multiple sclerosis: epidemiology, pathophysiology and managementBrendan J Kelley, Moses RodriguezPageof 211